创胜集团-B(06628)：创胜医药于ESMO Asia公布osemitamab三联疗法一线治疗胃或胃食管结合部腺癌的I/II期(Transtar102)更新疗效数据

智通财经网2025-12-05

智通财经APP讯，创胜集团-B(06628)发布公告，公司董事会欣然宣布，osemitamab联合纳武利尤单抗与CAPOX作为胃或胃食管结合部腺癌(TranStar102)一线治疗的I/II期临床试验(Transtar102)G 队列基于CLDN18.2和PD-L1表达的更新疗效分析。该研究结果以壁报形式(摘要编号：#299P)亮相于在新加坡举行的欧洲肿瘤内科学会亚洲年会(ESMO Asia ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2589858430?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_12.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2025-12-05 06:25","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2589858430","market":"sg","top_or_hot":-1,"title":"创胜集团-B(06628)：创胜医药于ESMO Asia公布osemitamab三联疗法一线治疗胃或胃食管结合部腺癌的I/II期(Transtar102)更新疗效数据","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，创胜集团-B(06628)发布公告，公司董事会欣然宣布，osemitamab联合纳武利尤单抗与CAPOX作为胃或胃食管结合部腺癌(TranStar102)一线治疗的I/II期临床试验(Transtar102)G  队列基于CLDN18.2和PD-L1表达的更新疗效分析。该研究结果以壁报形式(摘要编号：#299P)亮相于在新加坡举行的欧洲肿瘤内科学会亚洲年会(ESMO  Asia ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1377938.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>创胜集团-B(06628)：创胜医药于ESMO Asia公布osemitamab三联疗法一线治疗胃或胃食管结合部腺癌的I/II期(Transtar102)更新疗效数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n创胜集团-B(06628)：创胜医药于ESMO Asia公布osemitamab三联疗法一线治疗胃或胃食管结合部腺癌的I/II期(Transtar102)更新疗效数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-05 06:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1377938.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，创胜集团-B(06628)发布公告，公司董事会欣然宣布，osemitamab联合纳武利尤单抗与CAPOX作为胃或胃食管结合部腺癌(TranStar102)一线治疗的I/II期临床试验(Transtar102)G  队列基于CLDN18.2和PD-L1表达的更新疗效分析。该研究结果以壁报形式(摘要编号：#299P)亮相于在新加坡举行的欧洲肿瘤内科学会亚洲年会(ESMO  Asia ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1377938.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1377938.html","article_id":"2589858430","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_12.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589858430","pubTimestamp":1764887126,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"创胜集团-B(06628)发布公告，公司董事会欣然宣布，osemitamab联合纳武利尤单抗与CAPOX作为胃或胃食管结合部腺癌(TranStar102)一线治疗的I/II期临床试验(Transtar102)G \n队列基于CLDN18.2和PD-L1表达的更新疗效分析。该研究结果以壁报形式(摘要编号：#299P)亮相于在新加坡举行的欧洲肿瘤内科学会亚洲年会(ESMO \nAsia Congress 2025)。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","06628":"创胜集团-B"},"translate_title":"Chuangsheng Group-B (06628): Chuangsheng Pharma announced the updated efficacy data of phase I/II (Transtar102) of osemitamab triple therapy for the first-line treatment of gastric or gastroesophageal junction adenocarcinoma at ESMO Asia","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"09939":1.5,"06628":1.5},"content_text":"智通财经APP讯，创胜集团-B(06628)发布公告，公司董事会欣然宣布，osemitamab联合纳武利尤单抗与CAPOX作为胃或胃食管结合部腺癌(TranStar102)一线治疗的I/II期临床试验(Transtar102)G  队列基于CLDN18.2和PD-L1表达的更新疗效分析。该研究结果以壁报形式(摘要编号：#299P)亮相于在新加坡举行的欧洲肿瘤内科学会亚洲年会(ESMO  Asia Congress 2025)。新分析结果进一步印证了osemitamab三联疗法所展现的令人鼓舞的临床获益。经过25.8个月的中位随访观察，在26例CLDN18.2表达≥40%、≥2  + 且PD-L1 CPS  已知的患者中，中位无进展生存期(mPFS)达到16.6个月，客观缓解率(ORR)为68%，中位缓解持续时间(mDoR)为18个月。值得关注的是，在PD-L1  CPS<1和≥1两个亚组中，CLDN18.2较高表达患者的PFS均优于较低表达患者，这表明  osemitamab的潜在治疗获益不受PD-L1表达水平影响，具有一致性。安全性特征与先前在ASCO 2025年大会上公布的数据一致。“探索性疗效分析持续表明，osemitamab联合标准治疗方案具有良好的临床获益，”  北京大学肿瘤医院消化肿瘤内科及I期临床试验病区主任，本次研究的主要研究者沈琳教授表示，“不同PD-L1亚组患者的获益一致性尤为值得关注，这表明该治疗方案有望为广大晚期胃或胃食管结合部腺癌患者带来具有临床意义的获益改善。”“我们欣喜地看到，本研究继续呈现出的强劲的临床获益信号，进一步印证了osemitamab具有为患者带来实质性获益的潜力，这些患者亟需更有效的治疗方案。”  创胜医药全球临床开发执行副总裁戚川博士表示，“此外，更新数据继续证实了osemitamab联合纳武利尤单抗与CAPOX作为晚期胃或胃食管结合部腺癌一线治疗方案具有良好的安全性与耐受性。”","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589858430","isCrawlerRequest":true}